Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. (Q53929198)

22 May 2018

title

Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. (English)

1 reference

22 May 2018

0 references

0 references

2

C A Tamminga

1 reference

22 May 2018

author name string

R R Conley

series ordinal

1

1 reference

22 May 2018

D L Kelly

series ordinal

3

1 reference

22 May 2018

C M Richardson

series ordinal

4

1 reference

22 May 2018

language of work or name

English

0 references

publication date

1 July 1999

1 reference

22 May 2018

published in

Biological Psychiatry

1 reference

22 May 2018

volume

46

1 reference

22 May 2018

issue

1

1 reference

22 May 2018

page(s)

73-77

1 reference

22 May 2018

Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900029-3

Evaluation of treatment-resistant schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900029-3

Time to clozapine response in a standardized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900029-3

Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900029-3

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900029-3

Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900029-3

Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900029-3

Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900029-3

Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900029-3

Clinical implications of clozapine discontinuation: report of an NIMH workshop.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900029-3

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900029-3

Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900029-3

Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900029-3

Adjunctive Use of Olanzapine in Mood Disorders: Five Case Reports

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900029-3

Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900029-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-3223(99)00029-3

1 reference

22 May 2018

1 reference

22 May 2018